识别阶梯楔形整群随机试验中的伦理问题以指导渥太华声明更新:2016-2022年发表试验的系统综述
本系统综述分析了2016-2022年发表的160项阶梯楔形整群随机试验(SW-CRT),旨在为渥太华声明更新提供依据。多数试验评估多层面干预(78项,49%),仅19项(12%)涉及治疗性患者干预;64项(40%)明确说明了使用整群随机和阶梯楔形设计的理由;157项(98%)报告了研究伦理委员会审查声明,其中148项(94%)报告获得批准;145项(91%)报告了知情同意声明。作者结论认为更新版渥太华声明应就研究参与者界定、知情同意要求、设计理由、伦理审查必要性及数据收集负担提供指导。
要点
- 160项SW-CRT中仅64项(40%)明确说明使用整群随机和阶梯楔形设计的理由。
- 157项(98%)报告伦理委员会审查声明,其中148项(94%)报告获得批准。
- 135项报告患者知情同意的试验中,55项(41%)未获取知情同意,其中42项(76%)提供了理由。
核心结论
- 更新版渥太华声明应就何时应将人视为研究参与者及何时需要知情同意、使用阶梯楔形设计的理由、伦理委员会审查的必要性以及SW-CRT中数据收集程序的负担提供指导。
研究设计与样本
- 系统综述,纳入2016-2022年以英文发表的评估健康干预措施的阶梯楔形整群随机试验的主要报告,共160项SW-CRT,由两名评价者独立提取数据,分歧通过共识解决。
主要发现
- 160项SW-CRT中,多数评估多层面干预(78项,49%),不常见涉及治疗性患者干预(19项,12%),少数(10项,6%)仅使用常规收集数据源进行结局评估。
- 64项试验(40%)明确说明了使用整群随机和阶梯楔形设计的理由。
- 157项(98%)包含研究伦理委员会审查声明,其中148项(94%)报告获得批准。
- 145项(91%)报告了知情同意声明,其中113项(78%)仅涉及患者,10项(7%)仅涉及医疗保健提供者,22项(15%)涉及两者。
- 在135项报告患者知情同意的试验中,55项(41%)未获取知情同意,其中42项(76%)提供了未获取同意的理由。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials (CRTs), published in 2012, is the first and remains the only international ethics guidance document specific to CRTs. However, the stepped-wedge CRT design raises complex ethical issues for which guidance may be lacking. The overarching objective of this review is to inform the forthcoming update of the Ottawa Statement; specific objectives are to characterize the types of interventions and data collection procedures in stepped-wedge CRTs (SW-CRTs), and to examine adherence to key ethical design, conduct, and reporting recommendations. STUDY DESIGN AND SETTING: Primary reports of SW-CRTs evaluating health interventions published 2016-2022 in English were reviewed. Two reviewers extracted data from each trial independently; discrepancies were resolved through consensus. RESULTS: Among 160 SW-CRTs, most evaluated multilevel interventions (78, 49%), and uncommonly involved therapeutic patient interventions (19, 12%). Few (10, 6%) exclusively used routinely collected data sources for outcome assessment. Sixty-four trials (40%) provided explicit justifications for using cluster randomization and the stepped-wedge design. Most (157, 98%) included a statement about research ethics committee (REC) review, of which 148 (94%) reported approval. A statement about consent was reported in 145 (91%), with 113 (78%) pertaining to patients only, 10 (7%) to health-care providers only, and 22 (15%) to both. Among 135 trials reporting on patient consent, consent was not obtained in 55 (41%). Justifications for not obtaining consent were provided in 42 (76%). CONCLUSION: The updated Ottawa Statement should provide guidance about when people should be considered research participants and when their consent is required, justifications for using a stepped-wedge design, the need for REC review, and the burden of data collection procedures in SW-CRTs. PLAIN LANGUAGE SUMMARY: We reviewed 160 SW-CRTs published between 2016 and 2022. These trials often evaluate multifaceted interventions delivered at the cluster or professional level rather than individual level, and most had to rely on at least some form of primary data collection. Although almost all SW-CRTs reported ethics review, fewer than half explained why they used the SW-CRT design, and a substantial minority did not include a statement about whether participant informed consent was obtained. Rarely did consent statement pertain to health-care providers; most statements pertained to patients. Among the SW-CRTs that had consent statements pertaining to patients, almost half reported not obtaining or waiving consent from them, and many of these did not report clear reasons for this. Our findings highlight the need for clearer guidance in the forthcoming update to the Ottawa Statement on the Ethical Design and Conduct of CRTs.
引用
- Goldstein CE, Shaw JF, Binik A, et al. Identifying ethical issues in stepped-wedge cluster randomized trials to inform the Ottawa Statement update: a systematic review of trials published 2016-2022. J Clin Epidemiol. 2025. PMID: 41241086. doi:10.1016/j.jclinepi.2025.112051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。